Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Imogam Market Expected To Reach $ Billion By 2030 At % CAGR
The rise observed in the historical timeframe was driven by elevated rabies death rates, insufficient initial availability of immunizations, dependence on passive immunity treatments, governmental vaccination initiatives for public health, and emergency medical services provided in hospitals.
The anticipated rise in the forecast period is driven by the growing frequency of animal bites, the broadening reach of rabies education initiatives, the development of emergency medical facilities, enhanced availability of immunoglobulins, and increased public funding for managing zoonotic diseases. Key developments expected during this time involve an ongoing need for rabies treatments after exposure, a wider application of passive immunization techniques, a heightened emphasis on preventing zoonotic illnesses, a surge in emergency immunoglobulin treatments, and improvements in public health readiness.
Download A Free Sample Report For Comprehensive Market Insights:
Imogam Market Industry Drivers: What Is Driving Revenue Growth?
The growing frequency of animal bites is anticipated to drive the expansion of the imogam market in the coming period. Animal bites occur when people are bitten by animals, resulting in injuries that often demand medical care. This rise in bite incidents stems from factors like an expanding pet population, insufficient animal control measures, and more frequent interactions between humans and animals. Imogam is administered for immediate post-exposure prophylaxis in victims of animal bites, offering passive rabies immunity until the rabies vaccine becomes effective. For example, in September 2024, an article from Dogster, a US-based bimonthly magazine and website, reported 6,000 dog bite incidents in 2023. Furthermore, fatalities linked to dog bites multiplied by five, increasing from 5 in 2022 to 15 in 2023. Consequently, the rising occurrence of animal bites is fueling growth in the imogam market.
The imogam market is expected to be driven forward by the upsurge in international travel. This increase reflects growing global mobility and tourism, propelled by factors such as relaxed restrictions, enhanced connectivity, and higher disposable incomes. Greater international travel amplifies exposure to regions where rabies is endemic, thereby boosting the need for imogam as an essential post-exposure treatment. In May 2024, according to the Office for National Statistics, a UK-based national statistical institute and leading independent producer of official data, overseas visitors to the UK climbed from 31.2 million in 2022 to 38.0 million in 2023. Thus, the escalating incidence of animal bites is stimulating the growth trajectory of the imogam market.
The expansion of healthcare infrastructure is set to propel the advancement of the imogam market in the future. Healthcare infrastructure encompasses the physical and organizational frameworks, facilities, resources, and systems needed to deliver medical services to the population. This expansion is fueled by an aging global demographic, a rise in chronic diseases, and technological innovations. A strong healthcare infrastructure is vital for the progress of Imogam Rabies-HT, enabling cold chain preservation, timely administration, and accessibility in rabies post-exposure prophylaxis. In May 2024, a report from the Office for National Statistics, a UK-based government agency, indicated that total healthcare spending increased by 5.6% in nominal terms from 2022 to 2023, compared to a 0.9% growth rate in 2022. Additionally, total long-term health and social care expenditure rose by 2.8% in real terms in 2022. Hence, the broadening of healthcare infrastructure is contributing to the growth of the imogam market.
Imogam Market Segmentation Trends And Revenue Drivers
The imogam market covered in this report is segmented –
1) By Patient Demographics: Pediatric Patients, Adult Patients, High-Risk Groups
2) By Application: Post-Exposure Prophylaxis, Pre-Exposure Prophylaxis
3) By Distribution Channel: Hospitals, Specialty Clinics, Online Pharmacies, Pharmacies
Imogam Market Industry Leaders: Which Organizations Are Driving Competition?
Major companies operating in the imogam market are Sanofi SA
Access The Complete Imogam Market Report:
Imogam Market Regional Outlook: Where Are The Largest Opportunities Located?
North America was the largest region in the imogam market in 2025. The regions covered in the imogam market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model